Actinium Pharmaceuticals
ATNM
34 hedge funds and large institutions have $18M invested in Actinium Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 3 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
21% more funds holding
Funds holding: 28 → 34 (+6)
11% more capital invested
Capital invested by funds: $16.3M → $18M (+$1.74M)
0.04% more ownership
Funds ownership: 0.28% → 0.32% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.09M |
| 2 |
PP
Patten & Patten
Chattanooga,
Tennessee
|
+$420K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$238K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$198K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$116K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$57.5K |
| 3 |
VFA
Virtus Fund Advisers
Hartford,
Connecticut
|
-$12K |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$7.14K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.78K |
ATNM Hedge Fund Activity: Q3 2014 in Review
34 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2014, worth a combined $18M — up 11% from $16.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ATNM positions and 3 closed out — a net gain of 6 holders — while 17 added to existing stakes and 4 trimmed.
The largest buyer was Northern Trust, adding an estimated $1.09M. The largest seller was Spark Investment Management, exiting entirely with an estimated $116K sold.
- 34 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2014, up from 28 in Q2 2014.
- Funds reported $18M of Actinium Pharmaceuticals stock for Q3 2014, up 11% quarter-over-quarter.
- 9 funds opened new Actinium Pharmaceuticals positions in Q3 2014 and 3 closed out, a net change of +6 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2014 was Northern Trust, an estimated $1.09M added.
- The largest Actinium Pharmaceuticals seller in Q3 2014 was Spark Investment Management, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2014.